Increased sensitivity of the ryanodine receptor to halothane-induced

oligomerization in malignant hyperthermia-susceptible human skeletal muscle by Glover, Louise et al.
TRANSLATIONAL PHYSIOLOGY
Increased sensitivity of the ryanodine receptor to halothane-induced
oligomerization in malignant hyperthermia-susceptible human skeletal muscle
Louise Glover,1 James J. A. Heffron,2 and Kay Ohlendieck3
1Department of Pharmacology, University College Dublin, Belfield, Dublin 4, Ireland; 2Irish Malignant
Hyperthermia Diagnostic Centre, Department of Biochemistry, University College Cork, Cork, Ireland;
and 3Department of Biology, National University of Ireland, Maynooth, County Kildare, Ireland
Submitted 20 May 2003; accepted in final form 2 September 2003
Glover, Louise, James J. A. Heffron, and Kay Ohlendieck.
Increased sensitivity of the ryanodine receptor to halothane-induced
oligomerization in malignant hyperthermia-susceptible human skele-
tal muscle. J Appl Physiol 96: 11–18, 2004. First published September
5, 2003; 10.1152/japplphysiol.00537.2003.—Mutations in the skeletal
muscle RyR1 isoform of the ryanodine receptor (RyR) Ca2-release
channel confer susceptibility to malignant hyperthermia, which may
be triggered by inhalational anesthetics such as halothane. Using
immunoblotting, we show here that the ryanodine receptor, calmod-
ulin, junctin, calsequestrin, sarcalumenin, calreticulin, annexin-VI,
sarco(endo)plasmic reticulum Ca2-ATPase, and the dihydropyridine
receptor exhibit no major changes in their expression level between
normal human skeletal muscle and biopsies from individuals suscep-
tible to malignant hyperthermia. In contrast, protein gel-shift studies
with halothane-treated sarcoplasmic reticulum vesicles from normal
and susceptible specimens showed a clear difference. Although the
2-dihydropyridine receptor and calsequestrin were not affected, clus-
tering of the Ca2-ATPase was induced at comparable halothane
concentrations. In the concentration range of 0.014–0.35 mM halo-
thane, anesthetic-induced oligomerization of the RyR1 complex was
observed at a lower threshold concentration in the sarcoplasmic
reticulum from patients with malignant hyperthermia. Thus the pre-
viously described decreased Ca2-loading ability of the sarcoplasmic
reticulum from susceptible muscle fibers is probably not due to a
modified expression of Ca2-handling elements, but more likely a
feature of altered quaternary receptor structure or modified functional
dynamics within the Ca2-regulatory apparatus. Possibly increased
RyR1 complex formation, in conjunction with decreased Ca2 up-
take, is of central importance to the development of a metabolic crisis
in malignant hyperthermia.
calcium homeostasis; excitation-contraction coupling; sarcoplasmic
reticulum; supramolecular complex; triad
ION CHANNELOPATHIES EXHIBIT recurrent patterns of mutations
and have common clinical features. Primary abnormalities
in Na, K, Ca2, and Cl channels may lead to hypoex-
citability resulting in periodic paralysis, hyperexcitability
causing myotonia, or susceptibility to malignant hyperther-
mia (MH) (23). The pharmacogenetic disorder malignant
hyperthermia is a potentially fatal, inherited myopathy,
characterized by a fulminant metabolic response to volatile
anesthetic agents in predisposed individuals (33, 39). The
symptoms of a hypermetabolic crisis, such as hypoxia,
acidosis, and hyperthermia, are widely attributed to a defect
of intracellular Ca2 homeostasis (31, 37). Changes in the
sensitivity of the sarcoplasmic reticulum (SR) Ca2-release
mechanism to various activating ligands, including haloge-
nated anesthetics and 4-chloro-m-cresol containing prepara-
tions of depolarizing muscle relaxants, have been reported
and characterized in susceptible skeletal muscle (21, 36, 43,
45, 49). Such changes are largely thought to represent the
phenotypic manifestation of point mutations in the major
MH-susceptible (MHS) locus, i.e., the gene encoding the
human skeletal muscle ryanodine receptor (RyR) 1 (RyR1)
Ca2 release channel (2). Over 20 mutations therein have
been defined (24, 33), accounting for susceptibility to MH in
over 50% of affected pedigrees (2). Furthermore, heterolo-
gous expression of mutated ryanodine receptors in human
embryonic kidney cells has been shown to confer an en-
hanced sensitivity of Ca2 release in response to halothane
compared with wild types (47). This strongly suggests that
these mutations alone are sufficient to produce susceptibility
to this muscular disorder, without the requirement for any
additional muscle-specific conditions (35).
Although Ca2 release from the SR in response to anesthet-
ics, such as halothane, is the generally accepted molecular
pathogenesis underlying an episode of MH (37), the exact
mechanism by which an anesthetic agent physically elicits
increased RyR1 channel opening is not well understood. An
intimate understanding of the molecular mechanism of general
anesthesia has preceded the true elucidation of such a process,
because the acceptance of proteins as primary molecular tar-
gets for volatile agents is a relatively recent advancement (12).
The traditional model of anesthetic action, a nonspecific per-
turbation of the phospholipid bilayer of neuronal membranes
(22, 29), has been largely discarded in favor of direct anesthetic
binding to protein targets (16). The major hypotheses of the
mechanism of general anesthesia suggest a variety of different
molecular scenarios (13), compounded by the enormous struc-
tural variations between agents displaying anesthetic potency.
Although no defined protein binding site has yet been identi-
fied, the predicted targets of these agents are hydrophobic sites
exhibiting some polar character, whose features are sufficiently
general to be widespread (13); primary candidates include the
hydrophobic internal cavity regions of ligand-gated ion chan-
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nels, whereby drug binding triggers anesthesia via potentiation
of postsynaptic inhibitory channel activity (16).
A number of observations have lent credibility to the idea of
proteins as anesthetic molecular targets. Volatile agents have
been shown to interact with model proteins such as bovine
serum albumin (11) and the firefly enzyme luciferase (16); both
examples are lipid-free, soluble proteins. The anomalous lack
of anesthetic potency of long-chain compounds (1) is most
simply described by anesthetics binding to protein pockets or
clefts with circumscribed dimensions (14). However, perhaps
the most compelling evidence for direct protein binding comes
from observations of stereoselectivity (15). Even the relatively
simple agent isoflurane displays stereoselective effects on neu-
ronal ion channels, a feature that does not extend to pure lipid
bilayers (15). What remains unresolved is the question of why
some proteins are highly sensitive to anesthetics whereas
others are not, and the nature of those protein binding sites that
define sensitivity. In addition, the structural and dynamic
consequences of anesthetic binding are relatively unknown and
difficult to demonstrate, given that the means to define protein
structure is in its relative infancy. Nevertheless, the indepen-
dent observations that inhalational anesthetics can bind to
proteins and then alter protein activity strongly indicate that a
change in protein conformation or dynamics must be occur-
ring (13).
To further characterize the SR from muscles of individuals
susceptible to MH and determine the conformational or dy-
namic consequences of halothane binding in normal vs. sus-
ceptible fibers, we have analyzed potential changes in the
abundance of key Ca2-regulatory proteins and investigated
halothane-induced effects on the quaternary structure of the
ryanodine receptor Ca2 release channel. Many studies on
human muscle pathophysiology have focused on the vastus
lateralis (48), making this particular muscle an excellent can-
didate for comparative research. We therefore prepared micro-
somal membranes from normal and MHS vastus lateralis
specimens and performed a comprehensive immunoblot anal-
ysis. Because the ryanodine receptor is closely associated with
various triad proteins (19, 24, 28, 30), we have investigated the
relative abundance of accessory marker components located in
the cytoplasm (calmodulin, RyR1-associated FK506 binding
protein FKBP12), the lumen of the SR [calsequestrin (CSQ),
annexin VI, calreticulin, sarcalumenin], the SR membrane
(junctin), and the junctional transverse tubules (dihydropyri-
dine receptor).
MATERIALS AND METHODS
Materials. Halothane (2-bromo-2-chloro-1,1,1-trifluoro-ethane)
was purchased from Sigma Chemical (Poole, Dorset, UK). Protease
inhibitors and peroxidase-conjugated secondary antibodies were ob-
tained from Chemicon International (Temecula, CA). Acrylamide
stock solutions were from National Diagnostics (Hessle Hull, UK),
and chemiluminescence substrates were purchased from Perbio Sci-
ence UK (Tattenhall, Cheshire, UK). Immobilin NC nitrocellulose
membranes were from Millipore (Bedford, MA). All other chemicals
were of analytical grade and purchased from Sigma Chemical.
Antibodies. Primary antibodies were purchased from Affinity
Bioreagents, Golden, CO [monoclonal antibodies VIIID12 to fast
CSQ, VE121G9 to the fast sarco(endo)plasmic reticulum Ca2-
ATPase (SERCA) 1 isoform of the Ca2-ATPase, IID8 to the slow
SERCA2 isoform of the Ca2-ATPase, XIIC4 to sarcalumenin, 1A to
the 1S-subunit of the dihydropyridine receptor, 20A to the 2-subunit
of the dihydropyridine receptor, 6D4 to calmodulin, and polyclonal
antibodies PA1-026 to FKBP12, and PA3-900 to calreticulin]; Upstate
Biotechnology, Lake Placid, NY (polyclonal antibody to the RyR1
isoform of the ryanodine receptor Ca2-release channel); Transduc-
tion Laboratories, Lexington, KY (monoclonal antibodies to annexin
II and annexin VI); Chemicon International (monoclonal antibody to
glyceraldehyde-phosphate dehydrogenase); and Sigma Chemical
(monoclonal antibodies MY-32 to the fast isoform and NOQ7.5.4D to
the slow isoform of the heavy meromyosin portion of myosin). A
polyclonal antibody raised against junctin was generously donated
by Dr. Steven Cala (Wayne State University School of Medicine,
Detroit, MI).
Isolation of microsomal membranes. Before membrane prepara-
tion, in vitro contracture testing (IVCT) of biopsied muscle for
susceptibility to MH was performed according to the European MH
group protocol (40). The microsomal fraction enriched in vesicles
derived from the SR was obtained from three MHS and three MH-
normal (MHN) biopsies after dissection of muscle fibers required for
IVCT. This was carried out with the express permission of each
patient and approved by the Ethics Committee of the Medical School
Fig. 1. Characterization of microsomes from malignant hyperthermia (MH)-
susceptible (MHS) human muscle. A: silver-stained gel. B: immunoblot labeled
with an antibody to glyceraldehyde phosphate dehydrogenase (GAPDH). C:
graphical presentation of the densitometric analysis of enhanced chemilumi-
nescence (ECL)-stained blots (n  3). There is no significant difference in the
expression of GAPDH in MH-normal (MHN) vs. MHS samples. Lanes 1 and
2 represent microsomal muscle membranes derived from MHN and MHS
individuals, respectively. Immunodecorated protein bands are marked by an
arrowhead, and molecular mass standards (103) are indicated on the left.
Table 1. IVCT data of MHS and MHN biopsied muscle
Patient Number
Amplitude of Halothane
Contracture at 0.54 mM, mN
Amplitude of Caffeine
Contracture at 2 mM, mN
MHS 1 5 2
MHS 2 16 3
MHS 3 23 8
MHN 1–3 0.0 0.0
Muscle was deemed as malignant hyperthermia susceptible (MHS) when
2% (vol/vol) halothane or 2 mM caffeine generated 2 mN force (40). Each of
the 3 normal (MHN) samples generated no detectable tension at the respective
halothane and caffeine concentrations.
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of University College Cork. Preparation of the heavy SR fraction from
human vastus lateralis muscle was carried out as previously described
(42). All procedures were carried out on ice at 0–4°C, and all isolation
buffers contained 5 g/ml of aprotonin, 5 g/ml of leupeptin, and 5
g/ml of pepstatin. The isolated membrane fraction was resuspended
at a final protein concentration of 10 mg/ml and stored at 70°C for
use within 1 mo of preparation. Ca2-ATPase activity was measured
as previously described (10), and protein concentration was deter-
mined according to the method of Bradford (5) with the use of bovine
serum albumin as a standard.
Incubation of muscle membranes with halothane. SR vesicles,
resuspended in 10 mM TrisCl, pH 7.0, 5 mM EGTA, 0.1 M NaCl, 0.3
M sucrose, were incubated for 30 min with 0.014–1.375 mM halo-
thane at 4°C. Halothane concentrations were based on previously
published procedures (27) estimating clinical levels of this drug to be
0.03–0.05 mol halothane per mole of lipid in the bilayer (46).
Halothane was added from an acetone-containing 50% (vol/vol) stock
solution. To detect halothane-induced complex formation, proteins
were treated with a nondenaturing buffer system before electro-
phoretic separation (17).
Gel electrophoresis and immunoblot analysis. Polyacrylamide gel
electrophoresis was performed under native, semi-native, or denatur-
ing conditions, as previously described in detail (7, 17). Electro-
phoretic analyses were carried out by use of 5% (wt/vol) or 6%
(wt/vol) resolving gels with a 4% (wt/vol) stacking gel, employing a
Mini-Protean III electrophoresis system from Bio-Rad Laboratories
(Hemel Hempstead, Herts, UK). Electrophoretic transfer to nitrocel-
lulose sheets for 70 min at 100 V, incubation with primary and
peroxidase-conjugated secondary antibodies, as well as immunodeco-
ration and visualization by enhanced chemiluminescence were per-
formed according to established methods (4). Densitometric scanning
of enhanced chemiluminescence blots was carried out on a Molecular
Dynamics 300S computing densitometer (Sunnyvale, CA) with Im-
ageQuant V3.0 software.
RESULTS
After the diagnostic evaluation of biopsied vastus lateralis
muscle specimens for susceptibility to MH by IVCT (Table 1),
this study focused on the analysis of microsomal membranes
derived from MHS muscle (Fig. 1), evaluated potential
changes in the expression of ryanodine receptor-associated
proteins (Figs. 2 and 3), determined halothane-induced effects
on the quaternary structure of protein complexes of the SR
(Figs. 4–6), and measured the effect of halothane on Ca2-
ATPase activity. Our immunoblot survey included accessory
Ca2-release channel markers of the cytoplasm, the lumen and
membrane of the SR, and the junctional transverse tubules. To
determine whether the mutant status of MHS SR is reflected by
modified protein complex formation, we performed compara-
tive protein gel-shift analyses with halothane. Because of the
relative scarcity of human tissue material available, this study
had to be performed with a limited amount of both individual
samples and total amounts of available tissue.
Characterization of MHS vastus lateralis muscle. As shown
in Table 1, the diagnostic data clearly revealed susceptibility to
MH in patients MHS-1 to MHS-3. IVCT was carried out
according to the European MH group protocol. Muscle speci-
mens were deemed MHS when 0.54 mM halothane and 2 mM
caffeine generated 2 mN force (40). Each of the three MHN
biopsies generated no detectable tension at the respective
caffeine and halothane thresholds. After IVCT analysis, micro-
somal membranes were prepared from tissue homogenates in
the presence of a protease inhibitor cocktail and electrophoreti-
cally separated. As illustrated in Fig. 1A, the overall protein
band pattern is relatively comparable between MHS and MHN
Fig. 2. Immunoblot analysis of the ryanodine receptor (RyR) in microsomes from MHS human muscle. Top: immunoblots labeled
with antibodies to the RyR (A), junctin (JUN) (B), calmodulin (CaM) (C), and the FK506 binding protein (FKBP12) (D). Bottom:
graphical presentation of the densitometric analysis of ECL-stained blots (n  3). There is no significant difference in the
expression of the analyzed proteins in MHN vs. MHS samples. Lanes 1 and 2 represent microsomal muscle membranes derived
from MHN and MHS individuals, respectively. Immunodecorated protein bands are marked by arrowheads, and molecular mass
standards (103) are indicated on the left.
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microsomes. The three main silver-stained clusters at 40,
100, and 200 kDa represent mostly actin, Ca2-ATPase, and
myosin, respectively. The slow and fast myosin heavy chain
(MHC) isoforms, often employed as indicators of general
fiber-type distribution in human muscle samples, did not ex-
hibit dramatic differences in their distribution in normal control
and MHS specimens (not shown). A key cytosolic marker that
appears to form a complex with the triadic Ca2-release
channel is the metabolic enzyme glyceraldehyde 3-phosphate
dehydrogenase. The results presented here indicate that the
expression of glyceraldehyde 3-phosphate dehydrogenase is
not affected in MH (Fig. 1B). Its relative expression was
unchanged in MHS compared with MHN myofibers (Fig. 1C).
Immunoblot analysis of Ca2-regulatory elements in hyper-
thermia-susceptible SR. Before our protein gel-shift experi-
ments, we analyzed the expression levels of a number of key
elements of Ca2 handling. Figure 2 displays representative
results of our immunoblot analysis of electrophoretically sep-
arated microsomal proteins and their densitometric evaluation.
Both the expression of the RyR1 Ca2-release channel and the
relative density of its putative binding elements was not dras-
tically changed between the two different specimens. Muta-
tions in the polypeptide sequence do not apparently translate to
differences in the relative abundance or electrophoretic mobil-
ity of the monomeric RyR subunit (Fig. 2A). No major changes
in the expression of the endogenous regulator junctin (Fig. 2B),
the RyR1-regulatory protein calmodulin (Fig. 2C), and the
RyR-associated FK506 binding protein FKBP12 (Fig. 2D)
were detected between MHN and MHS membrane vesicles.
In analogy to Figs. 1 and 2, the immunoblotting of markers
of Ca2 homeostasis did not reveal major differences in the
expression of abundant Ca2 pumps, Ca2-binding proteins,
and excitation-contraction coupling elements. The comparable
distribution of the fast-twitch SERCA1 isoform (Fig. 3A) and
the slow/cardiac SERCA2 isoform (Fig. 3B) of the SR Ca2-
ATPase between MHN and MHS vesicles agrees with the data
on the MHC isoforms. To address this question of whether
modified Ca2 cycling through the SR lumen might trigger
differences in the expression of ion reservoir elements and their
Ca2 storing ability in the MHS SR vs. the MHN SR, electro-
phoresed membrane fractions were probed for major skeletal
muscle and ubiquitous Ca2-binding elements. No major dif-
ferences between MHN and MHS SR vesicles were detected in
the abundance of the intraluminal protein calsequestrin (CSQ)
of the terminal cisternae and its high-molecular-mass isoforms
termed CLP (Fig. 3C), the longitudinal SR proteins sarcalu-
menin and 53-SRGP (Fig. 3D), or the minor Ca2 storage
element calreticulin (Fig. 3E). The abundance levels of the
main 1S-dihydropyridine receptor and its regulatory 2-sub-
unit were found not to be drastically different in MHS com-
pared with MHN muscle (Fig. 3, F and G). To evaluate
potential effects of modified Ca2 handling on abundant Ca2-
regulated elements, the widely distributed Ca2-dependent
phospholipid binding proteins of the annexin family were
studied. Both annexin II and annexin VI were shown to be not
affected in their relative expression in MHS specimens (Fig. 3,
H and I). The densitometric analysis of Ca2-regulatory ele-
ments is summarized in Fig. 3J.
Effect of halothane on protein complex formation in hyper-
thermia-susceptible SR. After treatment with halothane, micro-
somal proteins were analyzed by use of either native or
semi-native gel systems (17). As illustrated in Fig. 4, A and B,
incubation of native SR membranes derived from MHN and
MHS myofibers with 0.014–1.375 mM halothane did not
induce oligomerization of the native CSQ and CLP protein
species, implying that this intraluminal Ca2 binding element
probably does not represent a major target for halothane
binding. The oligomeric status of a typical triadic membrane
protein, the 2-dihydropyridine receptor, was also not affected
by halothane (Fig. 4, C and D). In contrast, although the
vehicle solvent acetone had no effect on the electrophoretic
mobility of SERCA1 protein bands separated under semi-
native conditions, incubation with halothane reduced the inten-
sity of immunodecoration of the apparent monomer band and
clearly caused the appearance of a high-molecular-mass com-
plex in both MHN and MHS membrane vesicles (Fig. 5, A and
C). Concentrations of halothane required to induce SERCA1
complex formation were found to be comparable between
normal and MH SR microsomes (Fig. 6A).
Fig. 3. Immunoblot analysis of key Ca2-regulatory proteins in microsomes
from MHS human muscle. Shown are immunoblots labeled with antibodies to
the fast-twitch sarco(endo)plasmic reticulum Ca2-ATPase (SERCA) 1 iso-
form (A) and the slow/cardiac SERCA2 (B) isoform of the sarcoplasmic
reticulum Ca2-ATPase, calsequestrin (CSQ) and CSQ-like proteins (CLPs)
(C), sarcalumenin (SAR), and the SR glycoprotein of 53 kDa (53-SRGP) (D),
calreticulin (CAL) (E), the 1S-subunit (F), and the 2-subunit (G) of the
dihydropyridine receptor (DHPR), as well as annexin II (ANX II) (H) and
annexin VI (ANX VI) (I). Immunodecorated protein bands are marked by
arrowheads. J: graphical presentation of the densitometric analysis of ECL-
stained blots (n 3). There is no significant difference in the expression of the
analyzed proteins in MHN vs. MHS samples. Lanes 1 and 2 represent
microsomal muscle membranes derived from MHN and MHS individuals,
respectively.
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However, halothane-induced oligomerization of the native
RyR1 protein species was shown to occur at lower levels of the
volatile agent in MHS (Fig. 5D) compared with MHN (Fig. 5B)
SR vesicles. The immunodecoration of a RyR1 containing
high-molecular-mass complex in anesthetic-treated MHS ves-
icles is clearly apparent at a concentration of 0.07 mM halo-
thane, a severalfold lower concentration than that required to
induce oligomerization of MHN RyR1 (Fig. 6B). Importantly,
this oligomerization of RyR1 induced by halothane treatment
does not apparently translate to intraluminal CSQ (Fig. 4, A
and B) or the triadic dihydropyridine receptor (Fig. 4, C and
D), suggesting that changes in the quaternary conformation of
the Ca2 release channel itself, rather than halothane-mediated
interactions with associated proteins, may underlie increased
channel opening.
As previous studies have demonstrated a depressed Ca2-
dependent ATPase activity of SERCA isoforms on halothane
binding, the Ca2 ATPase activity of MHN and MHS SR
Fig. 4. Effect of halothane on the oligomeric status of CSQ and
the 2-dihydropyridine receptor in microsomes from MHS
human muscle. Shown are immunoblots of microsomal mem-
branes from MHN (A, C) and MHS (B, D) muscle fibers,
labeled with antibodies to CSQ (A, B) and 2-DHPR (C, D).
Lane 1 represents an untreated control (C) sample, lane 2 is a
vehicle (V) control with microsomes incubated with 5% (vol/
vol) acetone but no halothane, and lanes 3-7 represent micro-
somes incubated with 0.014, 0.07, 0.35, 0.69, and 1.38 mM
halothane, respectively. Immunodecorated monomers are indi-
cated by solid arrowheads, and the position of oligomeric
structures is marked by open arrowheads. Molecular mass
standards (103) are indicated on the left.
Fig. 5. Effect of halothane on the oligomeric status
of the Ca2-release channel and the Ca2-ATPase
in microsomes from MHS human muscle. Shown
are immunoblots of microsomal membranes from
MHN (A, B) and MHS (C, D) muscle fibers, labeled
with antibodies to the fast-twitch SERCA1 isoform
of the sarcoplasmic reticulum Ca2-ATPase (A, C)
and the ryanodine receptor Ca2-release channel
isoform RyR1 (B, D). Lane 1 represents an un-
treated control (C) sample, lane 2 is a vehicle (V)
control with microsomes incubated with 5% (vol/
vol) acetone but no halothane, and lanes 3-7 repre-
sent microsomes incubated with 0.014, 0.07, 0.35,
0.69, and 1.38 mM halothane, respectively. Immu-
nodecorated monomers are indicated by solid ar-
rowheads, and the position of oligomeric structures
is marked by open arrowheads. Molecular mass
standards (103) are indicated on the left.
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vesicles was measured in the absence of anesthetic, at a low
halothane concentration (0.07 mM) and at a 10-fold higher
halothane concentration (0.69 mM). The Ca2-dependent en-
zyme activity of SR Ca2-ATPase was measured as the con-
centration of inorganic phosphate liberated per minute via ATP
hydrolysis. SERCA activity was most significantly depressed
in MHS SR vesicles, compared with control MHN enzyme
activity (not shown), suggesting that a drug-mediated cluster-
ing of Ca2 pump units causes an inhibition of enzyme
functioning.
DISCUSSION
Ca2 is an important physiological regulator, and because of
its relative abundance and complex interactions with various
groups of muscle proteins it also plays a central role in the
pathophysiology of many muscular disorders (3). In normal
skeletal muscle, Ca2 cycling through the various intracellular
compartments of fibers is maintained under precise temporal
and spatial control. Proper Ca2 handling requires a complex
membranous system for the efficient efflux and reuptake of
Ca2 ions. Abnormal Ca2 handling leads inevitably to cellu-
lar dysfunction. As outlined in recent reviews on the proposed
molecular mechanism of MH (24, 33), defective excitation-
contraction coupling and impaired Ca2 uptake underlie this
muscular disorder. Here, we could show that halothane has a
direct effect on the complex formation of the ryanodine recep-
tor Ca2-release channel.
Before the analysis of Ca2-regulatory elements, we wanted
to establish the general fiber-type distribution in the specimens
investigated. The isoform expression patterns of the SR Ca2-
ATPase and the MHC both demonstrated a heterogeneous fiber
population in the investigated muscle specimens. The SR from
MHS individuals is believed to recycle Ca2 at a higher rate,
as efflux from MH RyR1 Ca2-release channels is continu-
ously elevated compared with normal muscle, even during
relaxation (42). This, however, does not appear to result in
increased levels of SERCA expression. The slow and fast
MHC isoforms are good indicators of general fiber-type dis-
tribution in total human skeletal muscle extracts (8), but in SR
samples the interpretation of their expression levels is compli-
cated because of the fact that both proteins probably represent
a heterogeneous mixture of myosin species within vesicular
membrane preparations. We did not observe dramatic differ-
ences in the distribution of slow and fast MHC in normal
control and MHS specimens, which indicates that the biopsied
samples do not exhibit major differences in their fiber-type
composition. Thus our immunoblot survey was not influenced
by differences in isoform expression patterns. However, MHC
species found in muscle microsomes originally derive from
both the homogenized contractile apparatus and a molecular
subpopulation of “easy-releasable” myosins. The secondary
attachment and/or entrapment of these proteins in microsomal
vesicles during tissue homogenization and subcellular fraction-
ation cannot be sufficiently controlled. Therefore, one cannot
conclusively determine the exact fiber-type composition of the
biopsy sample from the relative content of the fast and slow
MHC isoforms present in the microsomal vesicle preparation.
However, one can exclude major differences between two
analyzed samples.
An abundant cytosolic enzyme that is potentially associated
with the triadic Ca2-release channel complex is represented
by glyceraldehyde 3-phosphate dehydrogenase (6, 34). We
could recently confirm the electrostimulation-induced decrease
in the expression of this marker of anaerobic-glycolytic energy
metabolism during fiber-type shifting (44) by immunoblotting
(41). Thus changes in the level of key enzymes involved in
energy metabolism can be used to detect changes in the
fiber-type composition of muscle biopsies. Here we could
show that the expression of glyceraldehyde 3-phosphate dehy-
drogenase is not affected in MH, indicating that the fulminant
hypermetabolic crisis observed in MH is not attributable to an
increase in this metabolic enzyme culminating in an enhanced
capacity of diseased fibers for glycolysis. It also shows that its
expression is not influenced by potential changes in its asso-
ciation to a mutated triad complex in MHS muscle.
Specific mutations in the RyR1 isoform of the SR Ca2-
release channel alone are sufficient to confer the autosomal
dominant MHS trait in a large percentage of MH families (33).
Because the ryanodine receptor does not exist in isolation in
the junctional triad membrane (38) but is closely associated
with other SR elements (20, 30), a mutated RyR1 receptor
could potentially trigger changes in the relative abundance of
other ion-regulatory proteins. However, our immunoblotting
survey did not detect a difference in the abundance or electro-
phoretic mobility of the RyR and its endogenous regulators
junctin, the FK506 binding protein of 12 kDa, and calmodulin.
The fact that the relative density of CSQ, CLPs, sarcalumenin,
and the 53-kDa SR glycoprotein are unaffected in MHS sam-
ples suggests that the decreased loading ability of MHS SR
vesicles (42) is not due to the depressed expression of key
Ca2-reservoir elements, but more likely a feature of altered
quaternary receptor structure and/or modified functional dy-
namics of key Ca2-binding proteins. Mutations in the dihy-
dropyridine receptor are also implicated in the molecular
Fig. 6. Halothane-induced oligomerization of the Ca2-release channel and
the Ca2-ATPase. Shown is the graphical presentation of the densitometric
analysis of the effect of halothane on the oligomeric status of the Ca2-ATPase
SERCA1 isoform (A) and the Ca2-release channel RyR (B) in microsomes
from MHN and MHS human muscle. Statistically very significant differences
are represented by ***P  0.001. Microsomes were incubated with 0.014,
0.07, 0.35, 0.69, and 1.38 mM halothane. Densitometric scanning of ECL blots
(n  3) was performed on a Molecular Dynamics 300S computing densitom-
eter (Sunnyvale, CA) with ImageQuant V3.0 software.
16 CALCIUM-RELEASE CHANNEL COMPLEX IN MALIGNANT HYPERTHERMIA
J Appl Physiol • VOL 96 • JANUARY 2004 • www.jap.org
 by 10.220.33.3 on O
ctober 5, 2016
http://jap.physiology.org/
D
ow
nloaded from
 
pathogenesis of MH (35), and because this transverse-tubular
protein directly interacts with the ryanodine receptor during
excitation-contraction coupling (28), it is interesting that the
expression of both -subunits of the voltage-sensing dihydro-
pyridine receptor are comparable in MHS and MHN. This
confirms the supposition that the MHS phenotype is attribut-
able to aberrant Ca2 channel function although not necessar-
ily due to abnormal expression levels of triadic Ca2 regula-
tory proteins. Cytoplasmic annexin VI is an accessory protein
of the supramolecular triad complex involved in excitation-
contraction coupling (24). Our immunoblotting suggests that
susceptibility to MH does not change its expression profile.
Hypersensitive gating of the major SR Ca2 release channel
appears to be the underlying defect in cases linked to the RyR1
MHS locus (9). The volatile anesthetics are noteworthy among
the drugs that may increase RyR1 activity and perturb Ca2
regulation, especially in MHS individuals. Although normal
skeletal muscle may tolerate a modest perturbation of Ca2
homeostasis, such as increased Ca2 leak from the SR, without
phenotypic evidence of a problem, myopathic MH muscle that
exhibits a leaky SR membrane because of mutated RyR1 Ca2
release channels may be compensated normally until perturbed
by an agent that further activates Ca2 release, thus further
straining homeostatic mechanisms (43). Because halothane has
a modulatory effect on SR Ca2 release at clinical concentra-
tions and has previously been shown to induce oligomerization
of several key SR components (7, 17, 18), the effects of
anesthetic complexation were investigated in MHN and MHS
SR vesicles. Our study clearly shows a reduced electrophoretic
mobility of halothane-treated RyR1. Possibly, stabilization of
the open channel conformation by halothane or aggregation of
the RyR1 channel complexes themselves may account for this
oligomerization pattern.
In analogy to findings reported on the cardiac isoform of the
SR Ca2 ATPase (25), halothane-induced aggregation of
SERCA molecules appears to inhibit enzyme functioning,
particularly in MHS SR vesicles at clinically relevant drug
concentrations. Previous studies suggest that the biomechani-
cal mechanism of halothane inhibition of Ca2 pump function
involves stabilization of an intermediate enzyme conformation
(26, 32). Halothane-mediated clustering might introduce con-
formational changes that inhibit proper subunit interactions,
thereby decreasing positive cooperativity within the physiolog-
ical Ca2 pump unit of the SR membrane (7, 26).
In conclusion, the findings of this study support two ideas: 1)
volatile anesthetics appear to directly influence sensitive pro-
tein-protein interactions within integral membrane protein
complexes and 2) the development of an anesthetic-mediated
crisis of MH may involve RyR1 protein complex formation.
Aberrant RyR1 channel function, resulting from mutations
within the amino acid sequence in MHS individuals, may be
exacerbated by such an anesthetic-mediated channel confor-
mational change, inducing prolonged opening of the Ca2
channel with reduced sensitivity to inactivating agents and
resultant elevation of myoplasmic Ca2 levels. In addition, the
results presented here also suggest a possible auxiliary role of
depressed SERCA activity in the molecular pathogenesis of
MH. Reduced resequestration of Ca2 ions back into the SR
lumen may contribute to sustained elevation of cytoplasmic
Ca2 ions and thus exacerbate metabolic activation and sus-
tained muscle contraction during an MH episode.
The sequence of pathophysiological events leading to halo-
thane-induced MH may be divided into the following steps. In
a normal individual, the Ca2-release channel complex is
regulated by direct coupling to the transverse-tubular dihydro-
pyridine receptor, local Ca2 levels, ATP, and various endog-
enous protein factors such as calmodulin, triadin, and CSQ.
Receptor stimulation triggers only transient channel opening,
and drug-induced disturbances of Ca2 homeostasis are
quickly rectified by the efficient Ca2 recycling via the action
of pumps, transporters, and binding proteins. In MH, the
mutated Ca2 channel exhibits an increased sensitivity to
activating agents, and clinical concentrations of volatile anes-
thetics trigger a prolonged channel opening. The enhanced
efflux of Ca2 ions from the SR, together with a decreased
Ca2-uptake rate, results in a prolonged elevation of cytosolic
Ca2 levels. This in turn triggers sustained muscle contraction,
metabolic activation, and membrane damage, resulting in the
main symptoms of malignant hyperthermia, i.e., muscle rigid-
ity, fiber damage, and heat production.
Although the pharmacological actions of inhalational anes-
thetics have not yet been classified in the general scheme of
receptor-mediated drug action, this study agrees with the hy-
pothesis that distinct binding sites exist in target proteins for
halothane. In contrast to the conventional view that general
anesthetics trigger nonspecific perturbation of biological mem-
branes, this study suggests that substances that may trigger
surgical anesthesia probably interact through specific hydro-
phobic binding sites within receptor complexes. The protein
gel-shift experiments presented here demonstrate that halo-
thane can directly interfere with the oligomeric status of the
Ca2-release channel complex. This clearly supports the pro-
tein theory of anesthetic action and sets the scene for the
elucidation of the binding domains involved in the action of
volatile anesthetics.
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